Human Stellate Cell Growth Media
For use with cell product HUCLS and HUCLS1.
For HUCLS-200K and HUCLS-1M, please see MST-500BK, StGM Bullet KitTM
Complete cell culture kit containing a cryopreserved ampule of lung fibroblast cells (catalog no. CC-2512) and FGMTM-2 BulletKitTM Fibroblast Growth Media (catalog no. CC-3132) for culture of lung fibroblast cells.
Human CD14+ monocytes, isolated from mobilized peripheral blood using positive immunomagnetic selection, ≥ 25 million cells, cryopreserved
Please note: This product will be discontinued once stock is depleted
Human CD14+ monocytes, isolated from mobilized peripheral blood using positive immunomagnetic selection, ≥ 10 million cells, cryopreserved
Please note: This product will be discontinued once stock is depleted
EGMTM-2 MV Microvascular Endothelial Cell Growth Medium-2 SingleQuotsTM Kit contains all supplements and growth factors required for Microvascular Endothelial Cells (basal media not included)
Cryopreserved ampule of Rat Neonatal DRG Neurons containing ≥ 200,000 cells
-
Natural Killer Cells InfographicNatural Killer cells have an innate ability to recognize and destroy non-self cells.
-
3D Natural Killer Cell-mediated Cytotoxicity AssayLonza White Paper
-
3D Natural Killer (NK) Cell-mediated Cytotoxicity (CMC) Assay -
Natural Killer (NK) Cell Expansion, Activation and Cytotoxicity AssayProtocol instructions
-
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
Transfection Protocol for Human NK Cells - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of human natural killer cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.
-
NK Cell Assay using 3D Bioprinted Tumor ModelsThis white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
-
TechSheet - Poietics™ Human Immune System CellsTechnical Product Information Sheet
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.